Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N-cyclooctylglycyl-N-(4-carbamimidoylbenzyl)-L-prolinamide is a synthetic small molecule with the molecular formula C23H35N5O2 and a molecular weight of 413.6 g/mol[1][3][6]. It is classified as an organic acid derivative, specifically an amide derivative of alpha amino acids[1][3]. The compound has been referenced in chemical and pharmacological databases but lacks detailed published information on its mechanism of action, clinical use, or therapeutic indication. No evidence was found for approval or advanced clinical development; it appears to be primarily characterized in chemical and experimental contexts.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on N-cyclooctylglycyl-N-(4-carbamimidoylbenzyl)-L-prolinamide.